NCT05807880 2026-01-23
ALTER-HN005
Sun Yat-sen University
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
NCT06516978 2024-07-24
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT05229003 2024-07-03
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Phase 2 Recruiting
NCT05493995 2024-05-09
PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT06341530 2024-04-02
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT05028504 2023-12-27
ALTER-GO-020
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT05494060 2023-11-07
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06114225 2023-11-02
PROMIS
Ruijin Hospital
Phase 2 Recruiting
NCT06081673 2023-10-13
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Recruiting
NCT06051851 2023-09-25
RCT-PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05885399 2023-06-02
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05726175 2023-02-13
Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer
West China Hospital
Phase 2 Unknown
NCT05519202 2022-08-29
Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer
The Central Hospital of Lishui City
Phase 2 Unknown
NCT05485350 2022-08-03
Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)
Peking University Third Hospital
Phase 2 Unknown
NCT05244993 2022-07-12
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT04970914 2022-03-08
ALTER-C003
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05265962 2022-03-04
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04952493 2022-01-28
Anlotinib or Penpulimab in Combination With RAI for DTC
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05137171 2021-11-30
AK105 Combined With Anlotinib in Patients With Cervical Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown